Dashboard
Manage Tickers

ACTU

Nasdaq actuatetherapeutics.com


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 6.19
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 09-24-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Actu...
09/23/2025 10:39:57

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles
Actuate Therapeutics Advances Elraglusib A...
09/22/2025 12:47:03

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 17:07:06

Core News & Articles
Actuate Therapeutics Prices $15M Public Of...
09/10/2025 12:39:17

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 12:11:03

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/09/2025 21:06:08

Core News & Articles
Actuate Therapeutics Announces Underwritte...
09/09/2025 20:19:35

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical compa...

Core News & Articles
Actuate Therapeutics Files For Mixed Shelf...
09/02/2025 20:38:52

-SEC Filing

this-actuate-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday
This Actuate Therapeutics Analyst Begins C...
08/26/2025 11:49:01

Core News & Articles
B. Riley Securities Initiates Coverage On ...
08/26/2025 10:22:43

B. Riley Securities analyst Mayank Mamtani initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and an...

Core News & Articles
HC Wainwright & Co. Reiterates Buy on Actu...
08/18/2025 10:31:41

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintain...

Core News & Articles
Actuate Therapeutics Q2 EPS $(0.30) Beats ...
08/14/2025 21:49:57

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of ...

Core News & Articles
Actuate Therapeutics Initiates Phase 1b Tr...
08/06/2025 12:47:03

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT ...

Core News & Articles
Actuate Therapeutics Initiates Planning Of...
07/17/2025 12:47:51

Core News & Articles
Actuate Therapeutics Announces End Of Phas...
07/17/2025 12:46:59

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
06/27/2025 12:07:16

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
06/26/2025 21:05:50

Core News & Articles
On June 25, 2025, Actuate Therapeutics Ent...
06/26/2025 12:15:25

 On June 25, 2025, Actuate Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Se...

Core News & Articles
Actuate Therapeutics Highlights Results Fr...
06/24/2025 13:22:04

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in ris...

Core News & Articles
Actuate Therapeutics Highlights Biomarker,...
06/20/2025 12:48:38

The poster described an analysis of 40 cytokines, chemokines, soluble cell receptors, and growth factors (CCSGs) from plasma sa...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION